

CURRICULUM VITAE

PERSONAL INFORMATION

Name: Barbara C. Tilley
Place of Birth: San Rafael, California
Phone: 713 500-9564 work
E-mail: Barbara.C.Tilley@uth.tmc.edu

EDUCATIONAL EXPERIENCE

1981 Ph.D., Biometry
University of Texas School of Public Health
Houston, Texas

1975 M.S. Biomathematics
University of Washington
Seattle, Washington

1972 B.A., Mathematics
California State University
Northridge, California

PRIMARY APPOINTMENTS

2009 – Present Professor and Director, Division of Biostatistics
Lorne D. Bain Distinguished Professorship in Public Health and Medicine
University of Texas, Health Science Center at Houston, School of Public Health
Houston, Texas

ADDITIONAL APPOINTMENTS

1999 - 2009 Department Chair, Biostatistics, Bioinformatics and Epidemiology
Medical University of South Carolina
Charleston, South Carolina

2005 – present Data and Safety Monitoring Board member
NIH NINDS Ceftriaxone in ALS

2004 – present Data and Safety Monitoring Board member
NIH NINDS CREST trial

2008 – present Data and Safety Monitoring Board member
NHLBI Practice Based Opportunities for Weight Reduction (POWER) Trial

2008 – present Data and Safety Monitoring Board member
NHLBI Long Term Oxygen Treatment Trial

To present Ad hoc reviewer for NIA, NINDS, NHLBI

PRIOR POSITIONS

2008 – 2009 Program Director (Biostatistics, Ethics)
Southeastern Clinical & Translational Research Institute (SECTR)

2004 – 2009 Data and Safety Monitoring Board member
University of Alabama Birmingham TEAR trial

2004 – 2007 Board of Advisors
NCHS/Academy Health Fellowship

2003 – 2006 Observational Study Monitoring Board member
NIH NIAMS Osteoarthritis Initiative (OAI)

2003 – 2006 Advisory Committee member
University of North Carolina at Chapel Hill and Shaw University, Carolina-Shaw
Partnership for the Elimination of Health Disparities

2005 – 2006 Ad hoc reviewer
NIH NINDS (Career development awards, Udall Centers)

2001 – 2003 Advisory Committee member
Voorhees College, Center of Excellence in Rural and Minority Health,

2000 - 2001 Chair of Data and Safety Monitoring Committee
Aventis Studies of Riluzole in Parkinson Disease,

1999 – 2004 Consultant
FDA Advisory Committee on Arthritis

1998 - 1999 Professor with tenure
Epidemiology and Biostatistics
Case Western Reserve University
Cleveland, Ohio

1998 Early Detection Implementation Committee member
NIH NCI

1997 - 2001 Data and Safety Monitoring Board member
NIH NIA, ACTIVE Trial

1997 - 2001 Health Care Quality and Effectiveness Research Study Section member
AHRQ

1997 – 2000 Data and Safety Monitoring Board member
NIH NIAID, Clinical Studies of Chronic Lyme
Disease

1997 - 1999 Department Chair, Biostatistics & Research Epidemiology
Henry Ford Health Sciences Center
Detroit, Michigan

1997 - 1999 External Review Committee
Kimmel Cancer Center's Cancer Prevention and Control Science (CPCS) Division

1996 - 1999 Chair of Data and Safety Monitoring Board
NIH NINDS, Women's Estrogen for Stroke Trial (WEST)

1996 - 1998 FDA Advisory Committee on Arthritis

1994 - 1998 Director
Center for Medical Treatment Effectiveness Programs
In Diverse Populations and Resource Center on African American Aging Research
Henry Ford Health System
Detroit, Michigan

1993 - 1996 Data Safety and Monitoring Board member
NIH NHLBI, Raynaud's Treatment Study (RTS)

1993 - 1995 National Osteoporosis Data Group (NODG)
NIH NIAMS

1992 - 1998 Data and Safety Monitoring Committee member
NIH NCI, NSABP Breast Cancer Trial of Tamoxifen,

1991 - 1995 Clinical Trials Committee, NIH NHLBI

1991 - 1992 Data and Safety Monitoring Board member, NIH NHLBI, Thrombolysis in Myocardial Ischemia (T3)

1991 Cervical Cytology Task Force member
Michigan Department of Public Health

1988 - 1997 Adjunct Associate Professor, University of Michigan
Ann Arbor, Michigan

1986 - 1998 Research Scientist, Michigan Cancer Foundation

1986 - 1992 Division of Cancer Biology and Diagnosis (DCBD) of the National Cancer Institute (NCI) Minnesota Colon Cancer Control Study Policy and Data Monitoring Group

1986 - 1989 Clinical Trials Committee
NIH NCI

1983 - 1987 Adjunct Assistant Professor
University of Michigan
Ann Arbor, Michigan

1983 - 1997 Division Head, Biostatistics & Research Epidemiology

Henry Ford Health Sciences Center
Detroit, Michigan

1982 - 1983 Head of Clinical Biostatistics Intermedics
Angelton, Texas

1980 - 1982 Section Head, Cancer Prevention
Assistant Professor, Biomathematics and Cancer Prevention
University of Texas System Cancer Center
M.D. Anderson Hospital and Tumor Institute, Division of Cancer Prevention

1980 - 1981 Biostatistical Consultant
DES Mothers and Breast Cancer Study
Dartmouth University

1978 - 1983 Biostatistical Consultant
National DESAD Project

1978 - 1980 Biostatistician
Beta-Blocker Heart Attack Trial (BHAT) and Hypertension Detection and Follow-up
Program (HDFP)
University of Texas School of Public Health, Houston, Texas

1978 - 1980 Faculty Associate
University of Texas School of Public Health, Houston, Texas

1976 - 1977 Statistical Consultant
Evaluation and Finance Subcommittee
Community Corrections Advisory Board
Dodge, Fillmore and Olmsted Counties, Minnesota

1974 - 1977 Biostatistician/Coordinator
National DESAD Project
Department of Medical Statistics and Epidemiology
Mayo Clinic and Mayo Foundation
Rochester, Minnesota

1973 - 1974 Biostatistical Consultant
Child Development and Mental Retardation Center
University of Washington
Seattle, Washington

PROFESSIONAL ORGANIZATIONS

1990 - present Society for Clinical Trials
Board of Directors (2004-2008)

1978 - present Caucus for Women in Statistics
President (1993)

1977 - present Biometric Society, ENAR

Regional Advisory Board (1983-85)
Regional Committee (1986-87)
Secretary/Treasurer (1987-1989)
President (1991)

1975 - present American Public Health Association
Nominating Committee for Statistics Section (1983)
Statistics Section Council (1986-88)
Statistics Awards Committee (1986)
Spiegelman Award Committee (1987-1989)
Program Chair, Statistics Section (1990)
President, Statistics Section (1991)

1972 - present American Statistical Association
Program Chair, Biometric Section (1983)
Biopharmaceutical Section Executive Committee (1984-86)
Secretary, Biometrics Section, ASA (1986)
Fellow (1992)

CURRENT FUNDING

Movement Disorders Society (PI:Tilley) 11/01/04–10/31/10

Validating the Uniform Parkinson's Disease Rating Scale

The objective of this study is to complete cognitive interviewing, confirmatory factor analysis, comparison of old UPDRS to new MDS-UPDRS, assessment of instrument's ability to measure change over time, and assist international sites in developing translations.

6098-SP (PI: Tilley/transferred to Mainous) 07/01/08–06/30/10

Duke Endowment

Increasing Minority Participation in Clinical Research

The objective of the study is to increase minority participation in medical research for those institutions that comprise Health Sciences South Carolina (HSSC) as a step toward improving the health of racially and ethnically diverse communities in South Carolina.

U01 NS 43127 (PI: Tilley) 09/30/01–11/30/11

NIH/NINDS

Parkinson's Disease Clinical Trial: Statistical Center

The Medical University of South Carolina, Department of Biometry and Epidemiology serves as the Statistical Center for the Parkinson's Disease Neuroprotection Clinical Trial.

Completed Research Support

***1 T32 NS48007-01A1** (PI: Palesch) 07/01/05–06/30/10

NINDS/NIH

Biostatistics Training with Application to Neuroscience

Program Faculty/Mentor

The objective of this training grant is to train candidates at the pre-doctoral level, who will undertake dissertation research focused on biostatistical methodology with direct application to neuroscience research.

*I left MUSC so completed my effort on training grant.

****1 T32 RR023258-01** (PI: Tilley) 09/20/05–06/30/09

NCRR / NIH

Southeastern Pre-Doctoral Training in Clinical Research

This training grant is part of the NIH Roadmap initiative is to train pre-doctoral students from the six colleges at MUSC in clinical and translational research methods.

**When MUSC CTSA was funded 7/1/09 the T32 was rolled into the CTSA.

1 R01 NS052417-01 (PI: Levine) 07/15/05–05/31/08

Mt. Sinai School of Medicine (sub-contract) / NINDS

Recurrent Stroke Prediction: Optimizing aPL-P Biomarkers

1 R01 NS044976 (PI: Palesch) 09/01/04-11/31/07

NINDS/ UMDNJ

“Antihypertensive treatment in acute cerebral hemorrhage - Statistical Center”

Co-Investigator/Statistician

The objective of the study is to conduct a Phase I study to evaluate the safety of different levels of antihypertensive treatment in patients with cerebral hemorrhage.

5 P30 AG021677 (PI: Tilley) 09/30/02 – 08/31/07

NIH-NIA

SC Cooperative for Healthy Aging in Minority Populations – Resource Center for Minority Aging Research (SC CHAMP/RCMAR)

Administrative Core A

Measurement Core B

The long-term objective is to reduce the gap in health status differentials between older African Americans and Caucasians in South Carolina. The RCMAR research focuses on specific social, cultural and behavioral mechanisms leading to improved health and functioning.

T32 AG21794-03 10/01/02–04-30/07

IRMMA (PI: Mintzer)

NIH/NIA

Institute for Research Training on Mental Health and Aging

Role: Biostatistics Training Program Director

The aim of IRMMA is to recruit, train, and retain promising minority individuals from post-doctoral programs in research areas that relate to mental health and aging.

NIH P60 AR049459 (Silver) 04/15/03 -03/31/08

NIAMS

MCRC for Rheumatic Diseases in African-Americans

Methodology Core (Tilley)

Multidisciplinary Clinical Research Center grant consisting of 3 cores and 3 clinical research projects. The grant focuses on the effects of scleroderma and systemic lupus erythematosus, particularly in African-Americans. Dr. Tilley heads the Methodology Core, which provides statistical and bioinformatics support for the other cores and projects.

5 P01 HS10871 (PI: Tilley) 09/21/00 – 08/31/06

Agency for Health Care Research & Quality (AHRQ)

Understanding & Eliminating Health Disparities in Blacks

Administrative Core

The major goal of this project is to move beyond the identification and description of African American/Caucasian health-related disparities to understanding the disparities within the African American population and identifying solutions designed to address these health issues.

5 U010 DA013727-05 (PI: Brady) 9/30/00 - 8/31/05 3.75%
NIH/NIDA

Southeastern Node of the Clinical Trials Network

As part of NIDA's Clinical Trials Network, the South Carolina Node will attempt to bridge the gap between research and community based settings by developing an infrastructure to allow for the conduct of substance abuse psychological and pharmacological research trials.

NIH-NINDS R01 NS39160-01A1 Broderick and Palesch (PI) 09/30/00-06/30/03

Interventional Management of Stroke (IMS) Study

A Phase II trial of intra-arterial t-PA in addition to intravenous t-PA for patients with acute ischemic stroke.

Role: Co-investigator in
Statistical Center

NIH/NINDS 1 R01 NS40406-02 Ginsberg (PI) (Palesch, Subcontract) 01/05/01-07/31/04

University of Florida

Human Serum Albumin Therapy for Stroke

Role: Co-investigator

N01-NS-2-2343 (PI: Tilley) 04/01/02 – 01/31/06

KAI, Inc.

t-PA Stroke Trial

Analysis of t-PA trial data and collaboration with t-PA investigators.

1R21DK66066-01A1 (PI: Mainous) 07/01/04 – 06/30/06

NIDDK

Racial Disparities in Diabetes in the US and the UK

The primary aim of this study is to investigate whether differences in access to care are associated with differences in detection of diabetes as well as control, between racial and ethnic groups in the United States and the United Kingdom.

DOD/ONR SP0001

P.I.: Barbara C. Tilley, Ph.D.

“Occupational and Nutritional Risk Factors for Colon and Adenomatous Polyps in the Tri-Service”

6/1/00 – 5/31/02

\$87,705

Alpha One Foundation

P.I.: Charlie Strange, M.D.

“The Alpha One Foundation Research Registry”

7/1/00 – 6/30/02

\$71,795 (Total Year 2)

The Alpha One Foundation Research Registry enrolls patients with alpha-1 antitrypsin deficiency who are willing to participate in research. The Registry currently has >800 members. MUSC is the Registry coordinating center.

NIH-NINDS RO1 NS30820

P.I.: Steven R. Levine, M.D.

"Antiphospholipid Antibodies and Stroke"

9/27/93 - 6/30/02

\$1,810,705

To investigate the significance of antiphospholipid antibodies in ischemic stroke in the cohort of patients entered into the Warfarin Aspirin Recurrent Stroke Study Project.

NIH-NIA 5 P30 AG15286-05

P.I.: Barbara C. Tilley, Ph.D.

“Coordinating Center for the Resource Centers on Minority Aging”

9/1/97 – 8/31/02 \$158,757 (Total Cost, Year 5)
 Coordinating Center for African American Aging Research - The long-term objective is to reduce the gap in health status differentials between older African Americans and Caucasians.

NIH-NINDS 1NS 0 2382 P.I.: Barbara Tilley, Ph.D.
 "Phase II-B Randomized Controlled Study of Tissue Plasminogen Activator for Acute Ischemic Stroke - Coordinating Center"
 6/1/90 - 1/31/00 \$3,657,448
 A coordinating center for a randomized clinical trial of a treatment for stroke.

HS 98-002/AHCPR P.I. Susan Payne, Ph.D.
 "Managed Care/University Research and Training Partnership"
 8/1/98 - 7/31/99 \$59,136
 Program to explore the feasibility of distance learning targeting health professionals at Henry Ford Health System with an emphasis on minorities and to develop a curriculum for health services research on managed care.

AHCPR HS-07386 P.I. Barbara C. Tilley, Ph.D.
 "Medical Treatment Effectiveness Program"
 2/1/93 - 8/31/98 \$1,382,732
 Center goal is to use effectiveness trials to develop cost effective ways to prevent, diagnose, treat, and manage health problems to improve health outcomes for African Americans and provide training for African American investigators.

NIH-NINDS 2-PO1-NS23393-09A1 P.I.: Michael Chopp, Ph.D.
 "Center for Stroke Research"
 8/1/95 - 7/31/00 \$3,750,000
 Develop MRI as an essential tool for the identification and staging of stroke, to predict ultimate biological outcome from the ischemic event, and to employ MRI to assess and monitor the effects of therapeutic intervention.

NIH-NINDS P.I.: K.M.A. Welch, M.D.
 "Headache Research Center"
 Tilley, PI of Biostatistics Core)
 9/1/95 - 8/31/97 \$3,747,103
 The overall goal of this proposal is to investigate the cause, mechanisms, and consequences of migraine.

NIH-NCI 5-RO1-CA52605 P.I.: Barbara Tilley, Ph.D.
 "Colorectal Cancer Screening and Nutrition Intervention"
 5/1/91 - 4/30/96 \$2,864,919
 Intervention study to modify diet and increase screening participation among pattern and model makers.

NIH-NHLBI N01-AR-1-2202 P.I.: Barbara Tilley, Ph.D.
 "Coordinating Center for an Assessment of the Efficacy of Minocycline in the Treatment of Rheumatoid Arthritis"
 3/1/91 - 9/30/96 \$1,342,883
 A multi center, randomized, double-blind clinical trial of Minocycline vs. Placebo for the treatment of rheumatoid arthritis.

MPHI

P.I.: Barbara Tilley, Ph.D.

"Cardiovascular Disease Prevention Among African Americans"

11/1/95 - 12/15/96

\$25,000

A pilot study of a church-based nutrition and exercise intervention for African American men.

HONORS AND AWARDS

MUSC Distinguished Faculty Service Award 2007

MUSC Distinguished University Professor 2006

10th International Congress of Parkinson's Disease & Movement Disorders 2006

William Koller Memorial Fund Award

Statistics Section, Professional Merit Award - American Public Health Association – 1993

Fellow, American Statistical Association – 1992

University of Washington:

National Center for Health Services Research and Development Traineeship

California State University at Northridge:

Dean's List

Graduated Cum Laude

EDITORIAL REVIEW

2007- present Editorial Board, *Movement Disorders*

2000 Reviewer, *Journal of Nutrition Education* (Special issue on Nutrition Education and Aging)

1994 - 2003 Editor, *Stroke*

1993 - present Ad Hoc Reviewer, *American Journal of Public Health*

1990 - 1996 Editor, *Statistics in Medicine*

1989 - present Ad Hoc Reviewer, *American Journal of Epidemiology*

1987 - present Ad Hoc Reviewer, *Neurology*

1983 - 1995 Reviewer, *Journal of Vascular Surgery*.

PUBLICATIONS

* = students I have advised (not all as primary advisor);

+ = RCMAR scholars

1. Rajamani, K; Chaturvedi, S; Jin, Z; Homma, S; Brey, RL; **Tilley, BC**; Sacco, RL; Thompson, LP; Mohr, JP; Levine, SR; on Behalf of the PICSS-APASS Investigators. Patent Foramen Ovale, Cardiac Valve Thickening, and Antiphospholipid Antibodies as Risk Factors for Subsequent Vascular Events. The PICSS-APASS Study. *Stroke* (published online ahead of print June 4, 2009).
2. **The NINDS NET-PD Investigators**. Determinants of the Timing of Symptomatic Treatment in Early Parkinson Disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience. *Archives of Neurology* (in press 2009).
3. Magruder, KM, Ouyang*, B, Miller* ,S, **Tilley, BC**. Retention of Under-represented Minorities in Drug Abuse Treatment Studies. *Clinical Trials*, 2009; 6:252-260.
4. Nietert PJ, **Tilley BC**, Zhao W, Edwards PF, Wessell AM, Mauldin PD, Polk PP. Two pharmacy interventions to improve refill persistence for chronic disease medications: a randomized, controlled trial. *Medical Care*, 2009; 47(1): 32-40
5. Schneider MG, Swearingen* CJ, Shulman LM, Ye J, Baumgarten M, **Tilley BC**. Minority Enrollment in Parkinson's Disease Clinical Trials. *Parkinsonism and Related Disorders*, 2009;15(4):258-262.
6. Goetz CG, **Tilley BC**, Shaftman SR, et al. Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale Presentation and Clinimetric Testing Results. *Movement Disorders*, 2008; 23: 2129-2170.
7. **The NINDS NET-PD Investigators**. A Pilot Clinical Trial of Creatine and Minocycline in Early Parkinson's Disease: 18 Month Results. *Clinical Neuropharmacology*, 2008 May-Jun;31(3):141-50.
8. Carlozzi, N. E., Horner, M. D., Yang*, C., **Tilley, BC**. (2008). Factor analysis of the Repeatable Battery for Assessment of Neuropsychological Status. *Applied Neuropsychology*, 15(4), 1-6.
9. Mainous AG, Smith DW, Geesey ME, **Tilley, BC**. Factors Influencing Physician-Referrals of Patients to Clinical Trials. *Journal of the National Medical Association*, 2008;100(11): 1298-1303.
10. Simon DK, Swearingen* CJ, Hauser RA, Trugman JM, Aminoff MJ, Singer C, Truong D and **Tilley BC**. Caffeine and Progression of Parkinson's Disease. *ClinNeuropharm* , 2008; 31 (4) 189-196
11. Moreno-John G, Juarbe J, Diaz-Mendez M, Washington OGM, Lichtenbergp, Bridgewater p, Fleming C, Manson S, Noe T, Ford NE, **Tilley BC**, Mangione CM, Carrasquillo O, Perez-Stable E. Mentoring in community-based participatory research: the RCMAR experience. *Ethnicity and Disease* 2007; 17:S1-S33.
12. Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, Stern MB, **Tilley BC**, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N. Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, Format, and Clinimetric Testing Plan. *Movement Disorders*, 2007; Vol. 22, No. 1, pp. 41-47, <http://dx.doi.org/10.1002/mds.21198>
13. Elm* JJ, Kamp C., **Tilley BC**, Guimares P, Fraser D, Deppen P, Brocht A, Weaver C, Bennett S. Self-reported adherence versus pill count in Parkinson's disease: The NET-PD experience. *Mov Disord*. 2007 Apr 30;22(6):822-7.

14. Gonsalves⁺ WC, Gessey ME, Mainous AG, **Tilley BC**. A Study of Lower Extremity Amputation Rates in Older Diabetic South Carolinians. *The Journal of the South Carolina Medical Association*, 2007;103:4-7
15. Mainous AG, Koopman RJ, Diaz⁺ VA, Everett CJ, Wilson PW, **Tilley BC**. A Coronary Heart Disease Risk Score Based on Patient-Reported Information. *Am J Cardiol*, 2007;99:1236-1241
16. McQueen A, Vernon SW, Myers RE, Watts BG, Lee ES, **Tilley, BC**. Correlates and Predictors of Colorectal Cancer Screening among Male Automotive Workers. *Cancer Epidemiology Biomarkers*, 2007;16:500-509
17. **The NINDS NET-PD Investigators**. A randomized clinical trial of coenzyme Q₁₀ and GPI-1485 in Early Parkinson's Disease. *Neurology*, 2007; 68:20-28.
18. **Tilley BC**, Galpern, W. Screening Potential Therapies: Lessons Learned From New Paradigms Used in Parkinson's Disease. *Stroke*, 2007; 38: 800 - 803.
19. The NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. *Neurology*. 2006;66:664-671
20. Tanne D, Macko RF, Lin* Y, **Tilley BC**, Levine SR, NINDS rt-PA Stroke Study Group. Hemostatic Markers and Outcome of Intravenous rt-PA therapy for Acute Ischemic Stroke. *Stroke*, 2006; 37:704-704
21. Jauch EC, Lindsell C, Broderick J, Lin* Y, Fagan SC, **Tilley BC**, Levine, SR, and the NINDS rtPA Stroke Study Group. Association of Serial Biochemical Markers with Acute Ischemic Stroke: The NINDS rt-PA Stroke Study. *Stroke* 2006;37:2508 - 2513.
22. Mainous AG III, Baker R, Majeed A, Koopman RJ, Everett CJ, Saxena S, **Tilley BC**. English language skills and diabetes and hypertension among foreign born South Asian adults in England. *Public Health Reports*. 121:331-6, 2006 May-Jun.
23. Mainous AG III, Smith DW, Geesey ME, **Tilley BC**. Development of a Measure to Assess Patient Trust in Medical Researchers. *Annals of Family Medicine*. 4:247-52, 2006 May-Jun.
24. **Tilley BC**, Palesch YY, Kieburtz K, Ravina B., Huang P., Elm* J.J., Shannon K., Wooten G.F., Tanner C.M., Goetz C.G. (2005). Optimizing the Ongoing Search for New Treatments for Parkinson's Disease: Using Futility Designs. *Neurology*, 2006; 66:628-633.
25. Mainous AG III, Majeed A, Koopman RJ, Baker R, Everett CJ, **Tilley BC**, Diaz⁺ VA. Acculturation and diabetes among Hispanics: evidence from the 1999-2002 National Health and Nutrition Examination Survey. *Public Health Reports*, 2006:121:60-66.
26. Nietert PJ, Mitchell HC, Bolster MB, Shaftman SR, **Tilley BC**, Silver RM. Racial variation in clinical and immunological manifestations of systemic sclerosis. *Journal of Rheumatology*, 2006;33:263-268.
27. Palesch YY, **Tilley BC**, Sackett DL, Johnson KC, Woolson R. Applying a Phase II Futility Study Design to Therapeutic Stroke Trials. *Stroke*, 2005;36:2410-14.

28. Nietert PJ, Silver RM, Mitchell HC, Shaftman SR, **Tilley BC**. Demographic and clinical factors associated with in-hospital death among patients with systemic sclerosis. *Journal of Rheumatology*, 2005; 32:1888-1922.
29. Libman R.B, Kwiatkowski T, Lyden P, Grotta J, **Tilley BC**, Fagan S, Levine S, Broderick J, Lin Y, Lewandowski C, Frankel M. Asymptomatic hemorrhagic transformation of cerebral infarction does not worsen long - term outcome. *Journal of Stroke and Cerebrovascular Diseases*, 2005;14:50-54.
30. Nietert PJ, Mitchell HC, Bolster MB, Curran MY, **Tilley BC**, Silver RM. Correlates of depression, including overall and gastrointestinal functional status, among patients with systemic sclerosis. *Journal of Rheumatology*, 2005;32:51-57.
31. Guimaraes P, Kiebertz K, Elm* J, Palesch Y, Huang P, **Tilley, BC**, et al. Non-linearity of Parkinson's clinical progression: Implications for sample size calculations in clinical trials. *Clinical Trials*. 2:509-18, 2005.
32. Kwiatkowski T. Libman R. **Tilley BC**. Lewandowski C. Grotta JC. Lyden P. Levine SR. Brott T. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study.[see comment]. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] *Annals of Emergency Medicine*. 45:377-84, 2005.
33. Elm* J, Goetz CG, Ravina B, Shannon K, Wooten, GF, Tanner, CM, Palesch YY, Huang P, Guimaraes P, Kamp C, **Tilley B**, Kiebertz, K. A responsive outcome for Parkinson's disease neuroprotection futility studies. *Ann. Neurol*, 2005;57:197-203.
34. Carter* RE, Lipsitz SR, **Tilley BC**. Quasi-likelihood estimation for relative risk regression models. *Biostatistics*, 2005;1:39-44.
35. Mainous AG III, Cheng AY, Garr RC, Tilley BC, Everett CJ, McKee MD. Nonprescribed antimicrobial drugs in Latino community, South Carolina. *Emerg Infect Dis* 2005; 11:883-888.
36. Huang P, **Tilley BC**, Woolson RF, Lipsitz, S. Adjusting O'Brien's test to control type I error for the generalized nonparametric Behrens-Fisher problem. *Biometrics*. 2005, 61:532-539.
37. Levine SR, Brey RL, **Tilley BC**, Thompson JLT, Sacco RL, Padilla PA, Du E, Mohr JP, and The APASS Investigators. Concordance among aPL assays in ischemic stroke: A subset analysis of the WARSS/APASS Collaboration. *Thrombosis Res* 2004;114:607
38. Onitilo⁺ AA, Lin* Y, Okonofua EC, Ariail J, **Tilley B**. Race, education, and knowledge of bone marrow registry: Indicators of willingness to donate bone marrow among African Americans and Caucasians. *Transplantation Proceedings*, 2004; 36:3212-3219.
39. Pillemer SR, **Tilley BC**. Clinical trials, outcome measures, and response criteria. *The Journal of Rheumatology*, 2004; 31-3.
40. **The ATLANTIS, ECASS, and NINDS rt-PA Study Group Investigator**. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials, *Lancet*, 2004; 363:768-774.

41. **The IMS Investigators.** Combined Intravenous and Intra-arterial Recanalization for Acute Ischemic Stroke: The Interventional Management of Stroke (IMS) Study. *Stroke*. 2004; 35: 904-911.
42. Blixen CE, Bramstedt KA, Hammel JP, **Tilley BC.** A pilot study of health education via nurse-run telephone self-management programme for elderly people with osteoarthritis. *Journal of Telemedicine and Telecare*, 2004; 10:44-49.
43. **The Antiphospholipid Antibodies and Stroke Study (APASS) Investigators.** Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. *JAMA*, 2004; 291:576-584.
44. Lackland DT, Lin* Y, **Tilley BC,** Egan MG. An assessment of racial differences in clinical practices for hypertension at primary care sites for medically underserved patients. *The Journal of Clinical Hypertension*, 2004; 6:21-31.
45. Ford⁺ ME, Havstad SL, **Tilley BC;** Recruiting older African American men to a cancer screening trial (the AAMEN Project). *Gerontologist*, 2003; 43:27-34.
46. Tanne D, Levine SR, Brey RL, Lin* Y, Fagan SC, **Tilley BC;** for the NINDS rt-PA Stroke Study Group. Antiphospholipid-Protein Antibodies and Acute Ischemic Stroke in the NINDS rt-PA Stroke Trial. *Neurology*, 2003; 61:1158-1159.
47. Watts BG, Vernon SW, Myers RE, **Tilley BC.** Intention to be screened over time for colorectal cancer in male automotive workers. *Cancer Epidemiology, Biomarkers, and Prevention*, 2003; 12:339-349.
48. Pillemer S, Gulko P, Ligier S, Yarboro C, Gourley M, Goldbach-Mansky R, Siegel R, Hirsch R, Pucino R, **Tilley BC,** Wilder RL. Pilot clinical trial of intravenous doxycycline versus placebo for rheumatoid arthritis. *J. Rheumatol*, 2003; 30:41-3.
49. Higashida R, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, **Tilley BC,** Sacks D. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. *Stroke*, 2003; 34:e109-37
50. Bruno A, Levine SR, Frankel MR, Brott TG, Lin* Y, **Tilley BC,** Lyden PD, Broderick JP, Kwiatkowski TG, Fineberg SE, and the NINDS rt-PA Stroke Study Group. Relationship between admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. *Neurology*, 2002; 59:669-674.
51. **Tilley BC,** Elm* JJ. Improving health outcomes in diverse and vulnerable populations: Building on the experience of the centers for medical treatment effectiveness in diverse populations (MEDTEP). *Ethnicity & Health*, 2002; 7:227-230.
52. Ford⁺ ME, Havstad SL, Brooks BL, **Tilley BC.** Perceptions of diabetes among patients in an urban health care system. *Ethnicity & Health*, 2002; 7:243-254.
53. Wisdom⁺ K, Neighbors K, Williams VA, Havstad SL, **Tilley BC.** Recruitment of African Americans with type 2 diabetes to a randomized controlled trial using three sources. *Ethnicity & Health*, 2002; 7:267-278.

54. Lyden P, Lu M, Kwiatkowski, Frankel M, Levine S, Broderick J, Brott T, and the **NINDS rt-PA Stroke Study Group**. Thrombolysis in patients with transient neurologic deficits. *Neurology*, 2001;2115-2128.
55. Patel SC, Levine SR, **Tilley BC**, Grotta JC, Lu M, Frankel M, Haley EC, Brott, TG, Broderick JP, Horowitz S, Lyden PD, Lewandowski, CA, Marler JR, Welch KMA, for the NINDS rt-PA Stroke Study Group. Lack of clinical significance of early ischemic changes on computed tomograph in acute stroke. *JAMA*, 2001;286:2830-2838.
56. Voit, EO, **Tilley, BC**. Medical University of South Carolina – Master’s and doctoral programs in biostatistics, epidemiology, and biomedical informatics. *Qual Assur J.*, 2001;5179-181.
57. Mohr JP, et al (**Tilley BC** Consultant) A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. *NEJM* 2001; 345:1444-1451.
58. Lu M, **Tilley BC**. Use of odds ratio or relative risk to measure a treatment effect in clinical trials with multiple correlated binary outcomes: Data from the NINDS t-PA Stroke Trial. *Statistics in Medicine* 2001;20:1891-1901.
59. Broderick J, Lu M, Jackson C, Pancioli A, **Tilley B.**, Fagan S, Kothari R, Levine S, Marler J., Lyden P, Haley C, Brott T, Grotta J and the NINDS t-PA Stroke Trial Investigators. Apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke. *Annals of Neurology* 2001; 49:736-744.
60. Vernon SW, Myers RE, **Tilley BC**, Li S. Factors associated with perceived risk in automotive employees at increased risk of colorectal cancer. *Cancer, Epi, Biomarkers & Prevention*, 2001; 10:35-43.
61. The National Institute of Neurological Disorders and Stroke (NINDS) **rt-PA Stroke Study Group**: Effect of intravenous recombinant tissue plasminogen activator on ischemic stroke lesion size measured by computed tomography. *Stroke*, 2000, 31:2912-2919.
62. Frankel MR, Morgenstern LB, Kwiatkowski T, Lu M, **Tilley BC**, Broderick JP, Libman R, Levine SR, Brott R, for the NINDS rt-PA Stroke Study Group. Predicting prognosis after stroke. *Neurology*, 2000; 55:952-959.
63. Marler JR, **Tilley BC**, Lu M, Brott TG, Lyden PC, Grotta JC, Broderick JP, Levine SR, Frankel MP, Horowitz SH, Haley EC, Lewandowski CA, Kwiatkowski TP, for the NINDS rt-PA Stroke Study Group. Early stroke treatment associated with better outcome. *Neurology*, 2000; 55:1649-1655.
64. Lafata JE, **Tilley BC**, Nerenz D. Considerations in Deciding When and How to Evaluate Provider Group Interventions. *Health Services and Outcomes Research Methodology*, 2000; 1:49-62.
65. Kristal AR, Glanz K, **Tilley, BC**, Li S. Mediating factors in dietary change: Understanding the impact of a worksite nutrition intervention. *Health Education & Behavior*, 2000, 27:112-125.
66. **Tilley BC**, Pillemer SR, Heyse SP, Clegg DO, Alarcón GS, and The MIRA Trial Group. Global statistical tests for comparing multiple outcomes in rheumatoid arthritis trials. *Arthritis and Rheumatism*, 1999; 42:1879-88.

67. McDonald⁺ PE, **Tilley B C**, Havstad S L. Nurses' perceptions: Issues that arise in caring for patients with diabetes. *Journal of Advanced Nursing*, 1999;30: 425-430.
68. Borzak S, Joseph C, Havstad S, **Tilley B**, Smith ST, Housholder SD, Gheorghide M. Lower thrombolytic use for African Americans with myocardial infarction: an influence of clinical presentation? *American Heart Journal*. 1999 137:338-45.
69. Broderick JP, Adams, HP, Barsan W, Feinberg W, Feldmann E, Grotta J, Kase C, Krieger D, Mayberg M, **Tilley B**, Zambranski JM, Zuccarello M. Guidelines for the management of spontaneous intracerebral hemorrhage. *Stroke*, 1999; 30:905-915.
70. Kwiatkowski T, Libman R, Frankel M, **Tilley B**, Morgenstern L, Lu M, Broderick J, Lewandowski C, Marler J, Levine S, Brott T and NINDS rt-PA Stroke Study Group. Effects of tissue plasminogen activator for acute ischemic stroke at one year. *New England J. of Med.*, 1999; 340:1781-7.
71. Alarcon GS, **Tilley BC**, Li S, Fowler SE, Pillemer SR, for the MIRA Trial Group. Self-administered joint counts and standard joint counts in the assessment of rheumatoid arthritis. *Journal of Rheumatology*, 1999; 26:1065-1067.
72. **Tilley BC**, Glanz K, Kristal AR, Hirst K, Li S, Vernon SW, Myers R. Nutrition intervention for high-risk auto workers: Results of the next step trial. *Preventive Medicine*, 1999; 28:284-292.
73. **Tilley BC**, Vernon SW, Myers R, Glanz K, Lu M, Hirst K, Kristal AR. The next step trial: Impact of a worksite colorectal cancer screening promotion program. *Preventive Medicine*, 1999; 28:276-283.
74. Blixen CE, Havstad S, **Tilley BC**, Zoratti E. A Comparison of Asthma-Related Healthcare Use Between African-Americans and Caucasians Belonging to a Health Maintenance Organization (HMO). *Journal of Asthma*, 1999; 36: 195-204
75. Brott T, Lu M, Kothari R, Fagan SC, Frankel M, Grott JC, Broderick J, Kwiatkowski T, Lewandowski C, Haley EC, Marler JR, **Tilley BC**, and the NINDS t-PA Stroke Study Group. Hypertension and its Treatment in the NINDS rt-PA Stroke Trial. *Stroke*, 1998;29:1504-1509.
76. Fagan SC, Morgenstern LB, Petitta A, Ward RE, **Tilley BC**, Marler JR, Levine SR, Broderick JP, Kwiatkowski T, Frankel M, Walker MD, NINDS t-PA Study Group. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. *Neurology*, 1998;50:883-890.
77. Ford ME⁺, **Tilley BC**, McDonald PE. Social support among African American adults with diabetes: Part II A Review. *Journal of the National Medical Association*, July 1998; 90:424-432.
78. Ford ME⁺, **Tilley BC**, McDonald PE. Social support among African American adults with diabetes: Part I Theoretical Framework. *Journal of the National Medical Association*, June 1998; 90:361-365.

79. Joseph CLM, Havstad SL, Ownby DR, Johnson CC, **Tilley BC**. Racial differences in emergency department use persist despite allergist visits and prescriptions filled for anti-inflammatory medications. *J. Allergy and Clin Immunology*, April 1998; 101(Part 1):484-490.
80. Glanz K, Kristal A, Hirst K, **Tilley BC**. Psychosocial correlates of healthful diets among male auto workers. *Cancer Epidemiology, Biomarkers, and Prevention*, 1998; 7:119-26.
81. Myers RE, Vernon SW, **Tilley BC**, Lu M, Watts BG. Intention to Screen for Colorectal Cancer among White Male Employees. *Preventive Medicine*, 1998;27:279-87.
82. Ford⁺ ME, Havstad SL, **Tilley BC**, Bolton MB. Health outcomes among African American and Caucasian adults following a randomized trial of an asthma education program. *Ethnicity and Health*, 1997; 2:329-339.
83. Haley E, Lewandowski, C, **Tilley B**. Myths Regarding The NINDS rt-PA Stroke Trial: Setting the Record Straight (editorial). *Annals of Emergency Medicine*, 1997; 30:676-682.
84. **The NINDS t-Pa Stroke Study Group**. Intracerebral hemorrhage following intravenous t-PA therapy for ischemic stroke. *Stroke*, 1997; 28:2109 -118.
85. **The NINDS t-Pa Stroke Study Group**. Generalized efficacy of t-PA for acute stroke: Subgroup analysis of the NINDS t-PA Stroke Study. *Stroke*, 1997; 28:2119-125.
86. **Tilley BC**, Lyden PD, Brott TG, Lu M, Levine SR, Welch KMA, and the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Total quality improvement methodology reduces delays between emergency department admission and treatment of acute ischemic stroke. *Archives of Neurology*, 1997; 54:1466-74.
87. Blixen CE, **Tilley BC**, Havstad S, Zoratti E. Quality of life, medication use, and health care utilization of urban African Americans seen in emergency departments with asthma. *Nursing Research*, 1997; 46:338-341.
88. Vernon SW, Myers RE, **Tilley BC**. Development and validation of an instrument to measure factors related to colorectal cancer screening adherence. *Cancer Epidemiology, Biomarkers, and Prevention*, 1997; 6:825-32.
89. **The National Institute of Neurological Disorders and Stroke (NINDS)rt-PA Stroke Study Group**. A systems approach to immediate evaluation and management of hyperacute stroke. *Stroke*, 1997; 28:1530-1540.
90. Tuttleman M, Pillemer S. **Tilley BC**, Fowler S, Buckley L, Alarcón G, Trentham G, Neuner R, Clegg D, Leisen J. A cross sectional assessment of health status instruments in patients with rheumatoid arthritis participating in a clinical trial. *J. Rheumatol*, 1997; 24:1910-15.
91. Pillemer SR, Fowler SE, **Tilley BC**, Alarcón GS, Heyse SP, Trentham DE, Neuner R, Clegg DO, Leisen JC, Cooper SM, Duncan H, Tuttleman M, for the MIRA Trial Group. Meaningful improvement criteria sets in a rheumatoid arthritis clinical trial. *Arthritis and Rheumatism* 1997; 40:419-25.

92. Wisdom⁺ K, Fryzek JP, Spencer HJ, Anderson RM, Havstad SL, Dreiling MC, **Tilley BC**. African American and Caucasian differences in diabetes care and levels of disease control. *Diabetes Care* 1997; 20:971-77.
93. Bluhm GB, Sharp JT, **Tilley BC**, Alarcón GS, Cooper SM, Pillemer SR, Clegg DO, Heyse SP, Trentham DE, Neuner R, Kaplan DA, Leisen JCC, Buckley L, Duncan H, Tuttleman M, Fowler SE. Radiographic Results from the Minocycline in Rheumatoid Arthritis Trial (MIRA). *Journal of Rheumatology* 1997; 24:1295-302.
94. **Tilley BC**, Vernon SW, Glanz K, Myers R, Sanders K, Lu M, Hirst K, Smereka C, Kristal AR. Worksite cancer screening and nutrition intervention for high-risk auto workers: design and baseline findings of The Next Step Trial. *Preventive Medicine* 1997;26:227-235.
95. **The Antiphospholipid Antibodies and Stroke Study Group (APASS)**. Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death. *Neurology* 1997; 48:91-94.
96. **The Warfarin-Aspirin Recurrent Stroke Study (WARSS)**,The Antiphospholipid Antibodies and Stroke Study (APASS),The Patent Foramen Ovale in Cryptogenic Stroke Study (PICSS),The Hemostatis System Activation Study (HAS), The Genes in Stroke Study (GENESIS).The feasibility of a collaborative double-blind study using an anticoagulant: the Warfarin-Aspirin Recurrent Stroke Study, The Antiphospholipid Antibodies and Stroke Study, the Patent Foramen Ovale In Cryptogenic Stroke Study, and the Hemostatic System Activation Study. *Cerebral Vasc Surg* 1997;7:100-112.
97. Frankel M, for the **NINDS t-PA Stroke Trial Study Group**. The use of intravenous tissue-plasminogen activator for acute ischemic stroke: questions and answers on the NINDS t-PA Stroke Study. *The Neurologist*, 1996;5:1-9.
98. Eyler WR, Monsein LH, Beute GH, **Tilley BC**, Schultz LR, Schmitt WGH. Rib enlargement in patients with chronic pleural disease. *American Journal of Roentgenology* 1996;167:921-926 .
99. **Tilley BC**, Marler J, Geller N, Lu M, Legler J, Brott T, Lyden P, Grotta J. Using a global test for multiple outcomes in stroke trials with application to the NINDS t-PA Stroke Trial. *Stroke*, 1996; 27:2136-2141.
100. Reveille JD, Alarcón GS, Fowler SE, Pillemer SR, Neuner R, Clegg DO, Mikhail IS, Trentham DE, Leisen JCC, Bluhm G, Cooper SM, Duncan H, Tuttleman M, Heyse SP, Sharp JT, **Tilley B** for the MIRA Study Group. HLA-DRB1 genes and disease severity in rheumatoid arthritis. *Arthritis and Rheumatism*, 1996; 39:1802-1807.
101. Lamerato L, Ye E, **Tilley BC**. Using administrative data to develop a research agenda for a medical treatment effectiveness center. *The American Journal of Managed Care* 1996; 2:495-501.
102. Ford ME, Edwards G, Rodriguez J, Gibson RC, **Tilley BC**. An empowerment-centered, church-based, asthma education program for African American adults. *Health and Social Work* 1996; 21:70-75.
103. **Tilley BC**, Heyse SP, Rusinova M, Pillemer S, Clegg, DC. Global Tests for Multiple Outcomes in Rheumatoid Arthritis Trials. *British Journal of Rheumatology* 1995; 34(I Suppl):89.

104. **The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.** Tissue plasminogen activator for acute ischemic stroke. *N Eng J Med* 1995;333:1581-87.
105. **Tilley BC**, Vernon SW, Myers R, Glanz K, Lu M, Sanders K, Smereka C. Planning The Next Step: A screening promotion and nutrition intervention trial in the work site. *Annals of The New York Academy of Sciences* 1995;30:296-299.
106. Niland JC, Odom-Maryon TL, Lee J, **Tilley BC**. A survey of biostatistical consulting units throughout North America. *The American Statistician* 1995;49:183-189.
107. **Tilley BC**, Alarcón GS, Heyse SP, Trentham DE, Neuner R, Kaplan DA, Clegg DO, Leisen JC, Buckley L, Cooper SM, Duncan H, Pillemer SR, Tuttleman, M, Fowler SE. Minocycline in rheumatoid arthritis: A 48-week double-blind, placebo controlled trial. *Annals of Internal Medicine* 1995;122:81-89.
108. Lyden P, Brott T, **Tilley, BC**, Welch KMA, Levine S, Haley EC, Grotta J, Marler J and the NINDS t-PA Stroke Study Group. Improved reliability of the NIH Stroke Scale using video training. *Stroke* 1994;25:2220-2226.
109. NIH Consensus Statement on Optimal Calcium. (Served on panel that wrote the consensus statement.) *JAMA* 1994;272:1142-48.
110. Van Dyke D, Worsham M, Benninger M, Krause C, Baker S, Wolf G, Drumheller T, **Tilley BC**, Carey. Recurrent cytogenetic abnormalities in squamous cell carcinomas of the head and neck region. *Genes, Chromosomes and Cancer* 1994;9:192-206.
111. **The OSTR Collaborative Group.** Principal investigator for NINDS t-PA Stroke Trial registered with the Ottawa Stroke Trials Registry collaborative Group and the development of the Ottawa Stroke Trials Registry (OSTR). *Controlled Clinical Trials* 1994;15:503-511.
112. Gheorghide M, Shivkumar K, Schultz LR, Jafri S, **Tilley BC**, Goldstein S. Prognostic significance of electrocardiographic persistent ST depression in patients with their first myocardial infarction in the placebo arm of the Beta-Blocker Heart Attack Trial. *American Heart Journal* 1993;126:271-137.
113. Cortes P, Zhao X, Dumler F, **Tilley BC**, Atherton D. Age related changes in glomerular size and collagen content in rat and human. *J Am Soc Nephrol* 1992;2:1716-1725.
114. Kleerekoper M, Nelson D, Peterson EL, **Tilley BC**. Outcome variables in osteoporosis trials. *Bone* 1992;13 (Suppl 1):29-34.
115. Gheorghide M, Schultz L, **Tilley BC**, Rao S. Natural history of the first non-Q wave myocardial infarction in the placebo arm of the beta-blocker heart attack trial. *American Heart Journal* 1991;122:1549-1563.
116. Bradford CR, Kimmel KA, Van Dyke DL, Worsham MJ, **Tilley BC**, Burk D, del Rosario F, Lutz S, Tooley R, Hayashida DJS, Carey TE. Iip Deletions and breakpoints in squamous cell carcinoma: Association with altered reactivity with the UM-E7 antibody. *Genes, Chromosomes & Cancer*, 1991;3:272-282.

117. Bolton MB, **Tilley BC**, Kuder J, Reeves T, Schultz LR. The cost and effectiveness of an education program for adults who have asthma. *Journal of General Internal Medicine*, September/October, 1991;6:401-407.
118. Kleerekoper M, Peterson EL, Phillips E, Nelson DA, Schork MA, Parfitt AM, **Tilley BC**. A randomized trial of sodium fluoride in the treatment of postmenopausal osteoporosis. *Osteoporosis International*. 1991;1:155-161.
119. Johnson CC, Feingold M, **Tilley BC**. A meta-analysis of exposure to phenoxy acid herbicides and chlorophenols in relation to risk of soft tissue sarcoma. *Inter. Arch. Occup. Environment Health*, 1990;62:513.
120. **Tilley BC**, Johnson CC, Schultz LR, et al. Risk of colorectal cancer among automotive pattern and model makers. *J. Occup. Med.*, 1990;32:541-546.
121. **Tilley BC**, Kleerekoper M, Peterson EL, Phillips E, Nelson DA, Schork MA. Designing clinical trials of treatment for osteoporosis: Recruitment and follow-up. *Calcified Tissue Int*, 1990;47:327-331.
122. Nelson DA, Peterson E, **Tilley BC**, O'Fallon W, Chao E, Riggs L, Kleerekoper M. Measurement of vertebral area of spine x-rays in osteoporosis: Reliability of digitizing techniques, *J of Bone and Mineral Research*, 1990;5:707-716.
123. Gheorghide M, Schultz L. **Tilley BC**, Kao W, Goldstein S. Effects of propranolol in non-q-wave acute myocardial infarction in the Beta Blocker Heart Attack Trial. *Am J Cardiol*, 1990;66:129-133.
124. Nowinski GP, Van Dyke DL, **Tilley BC**, Jacobsen G, Babu RV, Worsham MJ, Wilson GN, Weiss L. The frequency of aneuploidy in cultured lymphocytes is correlated with age and gender but not with reproductive history. *Am. J. Hum. Genet*, 1990;46:1101-1111.
125. Jafri SM, **Tilley BC**, Peters R, Schultz LR, Goldstein S. Effects of cigarette smoking and propranolol in survivors of acute myocardial infarction. *Am J Cardiol*, 1990;65:271-276.
126. Berg T, Carretero OA, Guillermo AS, **Tilley BC**, Stewart JM. Role of kinin in regulation of rat submandibular gland blood flow. *Hypertension*, 1989;14:73-80.
127. Kleerekoper M, Peterson E, Nelson D, **Tilley BC**, Phillips E, Schork MA, Kuder J. Identification of women at risk for developing postmenopausal osteoporosis with vertebral fractures: Role of history and single photon absorptiometry. *Bone & Mineral*, 1989;7:171-186.
128. Robertson WM, Welch KMA, **Tilley BC**, Ewing JR. Cerebral blood flow asymmetry in the detection of extracranial cerebrovascular disease. *Stroke*, 1988;19:813-819.
129. Shih H, Webb CR, Conway WA, Peterson EL, **Tilley BC**, Goldstein S. Cardiac arrhythmias in chronic obstructive lung disease: Severity and significance. *Chest*, 1988;94:44-48.
130. Jafri SF, Rosman H, **Tilley BC**, Lakier J. Right ventricular ejection fraction and exercise capacity in patients with chronic heart failure due to ischemic or dilated cardiomyopathy. *Emory Univ Journal of Med*, 1988;2:77-79.

131. Ernst C, Elliott J, Ryan C, Abu-Hamad G, **Tilley BC**, Murphy R, Smith R, Reddy D, Szilagyi D. Recurrent femoral anastomotic aneurysms: A thirty-year experience. *Annals of Surg*, 1988;208:401-409.
132. Gheorghide M, Rosman H, Velardo B, Lakier J, Goldberg D, Friedman A, Schultz L, **Tilley BC**, Goldstein S. Risk identification at the time of coronary care unit admission in patient with suspected myocardial infarction. *Am Heart Journal*, 1988;116:1212-1217.
133. Jafri S, Khaja F, McFarland T, Capone R, Dahdah S, Haywood J, Edmiston W, **Tilley BC**, Schultz LR, Goldstein S. Efficacy of propranolol therapy after acute myocardial infarction related to coronary arterial anatomy and left ventricular function. *Am J Cardiol*, 1987;60:976-800.
134. Nathanson SD, Haas G, Bobrowski R, Lee M, **Tilley BC**, Schultz LR, Hetzel F. Regional lymph node and pulmonary metastases after local hyperthermia of melanomas in C57BL/6 mice. *International Journal of Radiation Oncology, Biology and Physics*, 1987;13:243-249.
135. Neale AV, **Tilley BC**, Vernon SW. Marital status, delay in seeking treatment and survival from breast cancer. *Soc Sci Med*, 1986;23:305-312.
136. Nathanson DS, Schultz LR, **Tilley BC**, Kambouris, A. Carcinomas of the colon and rectum: A comparison of staging classifications. *American Surgeon*, 1986;52:428-433.
137. **Tilley BC**, Schork A. Clinical Trials II: Randomization and sample size. *Henry Ford Hospital Med J*, 1985;33:219-224.
138. Ownby DR, Ownby HE, Bailey J, Frederick J, **Tilley BC**, Brooks SC, Russo J, Heppner G, Brennan M, and the Breast Cancer Prognostic Study Associates. Presurgical serum immunoglobulin concentrations and the prognosis of operable breast cancer. *JNCI*, 1985;75:655-663.
139. Welch WR, Robboy SJ, Kaufman RH, Townsend D, Noller KL, Gunderson J, Lawrence WD, Richart RM, O'Brien P, McGorray S, **Tilley BC**, Chazen G. Pathology of colposcopic findings in 2635 diethylstilbestrol-exposed young women. *Gynecologic Oncology*, 1985;21:277-286.
140. Magilligan DJ, Deepak V, Peper W, Allor D, Frinak S, **Tilley BC**. Failure of standard cardioplegia techniques to protect the conducting system. *The Annals of Thoracic Surgery*, 1985;39:403-408.
141. **Tilley BC**, Adam E, Barnes AB, Bergstarlh E, Labarthe D, Noller K, Colton T. A Comparison of pregnancy history recall and medical records: Implications for retrospective studies. *American Journal of Epidemiology*, 1985;121:269-281.
142. Nathanson DS, **Tilley BC**, Ma CK, Schultz LR, Smith RF. Perioperative allogeneic blood transfusions: Survival in patients with resected carcinomas of the colon and rectum. *Archives of Surgery*, 1985;120:734-738.
143. Vernon SW, **Tilley BC**, Neale AV, Steinfeldt L. Ethnicity survival and delay in seeking treatment for symptoms of breast cancer. *Cancer* 1985;55:1563-1571.
144. Magilligan D, Lewis JW, **Tilley BC**, Peterson E. The procaine bioprosthetic valve -twelve years later. *J Thorac Cardiovasc Surg*, 1985;89:499-507.

145. **Tilley BC.** Clinical trials: I. Design and ethical issues. *Henry Ford Hospital Med J*, 1984;32:147-151.
146. Robboy SJ, Noller KL, O'Brien P, Kaufman RH, Townsend D, Barnes AB, Gunderse J, Lawrence D, Bergstralh E, McGorray S, **Tilley BC**, Anton J, Chazen G. Increased incidence of cervical and vaginal dysplasia in 3,890 diethylstilbestrol (DES) exposed young women: experience of the national collaborative DES-Adenosis (DESAD) project. *JAMA*, 1984;21:2979-2983.
147. Spitz MR, **Tilley BC**, Batsakis JG, Gibeau JM, Newell GR. Risk factors for major salivary gland carcinoma. *Cancer*, 1984;54:1854-1859.
148. **Beta-Blocker Heart Attack Trial Research Group.** Beta-Blocker Heart Attack Trial: Design, methods, and baseline results. *Controlled Clinical Trials*, 1984;5:382-437.
149. Nash SN, **Tilley BC**, Kurland LT, Gundersen J, Barnes AB, Labarthe D, Donohew P, Kovacs L. Identifying and tracing a population at risk: The DESAD project experience. *American Journal of Public Health*, March 1983, pp. 253-258.
150. Neale AV, **Tilley BC**, Vernon SW, Steinfeldt L. Marital status differences in delay and survival among breast cancer patients (abstract). *The Gerontologist*, 1983;23 (Special Issue):179.
151. Barnes AB, Colton T, Gundersen J, Noller KL, **Tilley BC**, Strama T, Townsend DE, Hatab P, O'Brien P. Fertility and pregnancy outcome in women exposed in utero to DES. *N Eng J Med*, 1980;11:609-613.
152. Brian D, **Tilley BC**, Labarthe D, O'Fallon WM, Noller KL, Kurland LT. Breast cancer in DES mothers: lack of an association. *Mayo Clinic Proceedings*, 1980;55:89-93.
153. Robboy SJ, Kaufman RH, Prat J, Welch W, Gaffey T, Scully RE, Richart R, Fenoglio CM, Virata R, **Tilley BC**. Pathological changes - baseline findings of the DESAD project. *Obstetrics and Gynecology*, 1979, pp. 309-317.
154. O'Brien PC, Noller KL, Robboy SJ, Barnes AB, Kaufman RH, **Tilley BC**, Townsend D. Vaginal epithelial change - baseline findings of the DESAD project. *Obstetrics and Gynecology*, 1979, pp. 300-308.
155. Labarthe D, Adam E, Noller LL, O'Brien PC, Robboy S, **Tilley BC**, Townsend D, Barnes AB, Kaufman RH, Decker DG, Fish CR, Herbest AL, Gundersen J, and Kurland LT. Design and preliminary observations of national cooperative Diethylstilbestrol Adenosis (DESAD) Project. *Obstetrics and Gynecology*, 1978, pp. 453-458.
156. Professional and Public Relations Committee of the DESAD (Diethylstilbestrol and Adenosis) Project of the Division of Cancer Control and Rehabilitation. Exposure in utero to Diethylstilbestrol and related synthetic hormones: Associated with vaginal and cervical cancer and other abnormalities. *JAMA*, 1976;236:1107-1109.

LETTERS TO EDITOR

Alarcón GS, **Tilley BC**, Cooper S, Clegg DO, Trentham DE, Pillemer SR, Neuner R, Fowler S. Letter to the Editor. Another Look at Minocycline. *Bulletin on the Rheumatic Disease*, 1996;45:6-7.

Tilley BC, Johnson CC, Sandler M. Letter to the Editor. (Aneurysms of the abdominal aorta). *Arch Surg*, 1987;122:118-119.

Tilley BC. Letter to the Editor. (EC/IC Trial). *Surg Neurol*, 1987;27:504.

Adam E, Decker DG, Herbst AL, Noller KL, **Tilley BC**, Townsend D. Vaginal and cervical cancers and other abnormalities associated with exposure in utero in Diethylstilbestrol and related synthetic hormones. *Cancer Research*, 1977;37:1249-1251.

BOOK CHAPTERS

Tilley BC, Huang P, O'Brien PC. (November 2008) Global Assessment Variables. D'Agostino R, Sullivan L, Massaro J (Eds). In: Wiley Encyclopedia of Clinical Trials. John Wiley & Sons, Inc.

O'Brien PC, **Tilley BC**, Dyck PJ. (December 2007) Composite Endpoints in Clinical Trials. D'Agostino R, Sullivan L, Massaro J (Eds) In: Wiley Encyclopedia of Clinical Trials. John Wiley & Sons, Inc.

Tilley BC, Palesch YY. Conduct of Stroke-Related Clinical Trials. Mohr, JP, Choi, DW, Grotta JC, Weir B, Wolf PA. (Eds). Stroke: Pathophysiology, Diagnosis and Management, 4th Ed., Elsevier, 2004, Chapter 61, pp.1187-1207.

Tilley BC, Wisdom⁺ K, Sadler⁺ * ZE, Bradford WD. Overcoming barriers to the inclusion of older African Americans in health outcome research. In: L. Curry & J. Jackson (eds.), The science of Inclusion: Recruiting and Retaining Racial and Ethnic Elders in the Health Research, 2003, Chapter 8, 63-71. Washington, DC: The Gerontological Society of America.

Ford⁺ ME, Edwards G, Rodriguez J, Gibson RC, **Tilley BC**. An empowerment-centered, church-based, asthma education program for African American adults. Ewalt PL, Freeman EM, Poole DL. Community Building: Renewal, Well-being, and Shared Responsibility, NASW Press, Washington D.C., 1998.

The NINDS t-PA Stroke Trial: Progress Report. Yamaguchi T, Mori E, Minematsu K, del Zoppo GJ (eds), Thrombolytic Therapy in Acute Ischemic Stroke III, Springer-Verlag, Tokyo, 1995.

Tilley BC, Divine G. Analytical approaches to stroke clinical trials. Grotta J, Miller LP, Buchan AM (eds), Stroke Clinical Trials: Issues in Design, Conduct and Analysis, IBC, 1995.

Tilley BC. A Deming approach to recruiting: The National Institute of Neurological Disease and Stroke (NINDS) t-PA Stroke Trial Experience, for the NINDS t-PA Stroke Trial Investigators. Zoppo G, Mori E, Hacke W. (eds), Thrombolytic Therapy in Acute Ischemic Stroke II, Springer-Verlag Berlin Heidelberg, 1993.

Newell GR, Boutwell WB, Morris DL, **Tilley BC**, Branyon ES. Principles of epidemiology, in DeVita, V.T., Hellman, S., and Rosenberg, S.A. (eds), Cancer: Principles and Practice of Oncology, Philadelphia, J.B. Lippincott Company, 1982.

Tilley BC. Assessment of risks from DES: An analysis of research on these exposed during pregnancy or in utero, in Holmes, H.D., Hoskins, B.B., and Gross, M. (eds) The Custom-Made Child, Humana Press, 1981

TECHNICAL REPORTS

Tilley BC, Offord J, Oenning R. Data management for small scale observational studies. Technical Report Series, Section of Medical Research Statistics, Mayo Clinic, 14, February, 1981.

REVIEWS, 1999

Hirst K, **Tilley BC**. Clinical trials dictionary: Terminology and usage recommendations. Controlled Clinical Trials, 67.

ABSTRACTS OR POSTERS, 2008

BC Tilley, PJ Nietert,, W Zhao, PF Edwards, AM Wessell, PD Mauldin, PP Polk. “Randomized Trial of Pharmacy Interventions to Improve Chronic Disease Medication Refill Adherence”. 29th Annual Conference of the International Society for Clinical Biostatistics, August 2008

RT Brown, S Shaftman, PJ Nietert, **BC Tilley**, R Silver, L Mee, B Maxson, M Bonner, K Anthony, M Kral, J Wagner, M Connelly. ‘Enhancing Adjustment and Disease Adaptation Among Adolescent Females with Lupus’. International Society for Behavioral Medicine, 10th International Congress for Behavioral Medicine, August, 2008.

CG Goetz, **BC Tilley**, SR. Shaftman, S Fahn, P Martinez-Martin, W Poewe, CSampaio, M Stern, R Dodel, B Dubois, R Holloway, J Jankovic, J Kulisevsky, A Lang, A Lees, S Leurgans, P LeWitt, D Nyenhuis, C. Olanow, O Rascol, A Schrag, J Teresi, JJ van Hilten, GT Stebbins, ‘New Version of the UPDRS (MDS-UPDRS): Factor Analysis’. American Association of Neurology meeting, April, 2008.

ABSTRACTS OR POSTERS, 2007

Goetz CG, **Tilley B**, Shaftman S, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi J, van Hilten B. (2007). Clinimetric testing of the new UPDRS (MDS-UPDRS) vs. original version. 11th International Congress of Parkinson’s Disease and Movement Disorders in Istanbul, Turkey, June, 2007. Movement Disorders, 2007; Vol. 22, Suppl, 18.

Tilley, BC, Goetz, CG, Clinimetric testing of the new UPDRS (MDS-UPDRS) vs. original version. (abstract) MDS International Congress. Istanbul, Turkey June 3-7, 2007.

Rajamani K, Chaturvedi S, Jin Z, Homma S, Brey RL, **Tilley BC**, Sacc RL, Thompson JL, Mohr JP, Levine SR, Effect of Combined Echocardiographic Findings and Antiphospholipid on Vascular Outcomes in the PICSS/APASS Cohort. (abstract) 59th Annual Meeting of the American Academy of Neurology. Boston, MA, April 28-May 5, 2007.

Tilley, BC, Recruiting Older Diverse Populations into Studies of Parkinson s Disease: A Mixed Methods Approach to Development of an Intervention. (abstract) 9th Annual Meeting of the American Society for Experimental NeuroTherapeutics (ASENT). Washington, DC, March 8-10, 2007.

Tilley BC, Mainous A, Smith D, Elm J, Struman K, Recruiting Older Diverse Populations into Parkinson’s Disease (PD) Trials. American Society for Experimental Neurotherapeutics 9th Annual Meeting, Washington D.C. March 2007.

ABSTRACTS OR POSTERS, 2006

Carlozzi, NE, Horner, MD, Yang, C, **Tilley, BC**, Factor Analysis of the Repeatable Battery for the Assessment Of Neuropsychological Status. (abstract) Submitted to Archives of Clinical Neuropsychological, December 2006.

Tilley, BC, Struman, K. Recruiting Minorities Into Clinical Trials for Parkinson's Disease. Poster. The Gerontological Society of America's 59th Annual Scientific Meeting. Dallas, TX, November 18, 2006.

Knott, K, Tilley B, Carter, R, Nietert, P, Simpson, K, Egan, B, Obtaining confidence intervals for ranked data based on multiple health indicators. (abstract) Submitted to the Health Administration of the 134th Annual Meeting & Exposition. Boston, MA, November 4-8, 2006.

Galpern, WR, **NET-PD Investigators**, The NINDS (Bethesda, MD, USA). A randomized futility clinical trial of creatine and minocycline in early Parkinson disease – 18 months results. Abstracts of The Movement Disorders Society's Tenth International Congress of Parkinson's Disease and Movement Disorders. Kyoto, Japan, October 30-November 2, 2006.

Kieburtz, K., **The NINDS Clinical Investigator Group** (Rochester, NY, USA). A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson's disease. Abstracts of The Movement Disorders Society's Tenth International Congress of Parkinson's Disease and Movement Disorders. Kyoto, Japan, October 30-November 2, 2006.

ABSTRACTS OR POSTERS, 2005

Tilley BC. Evaluating the SF-36® and SF-12® in Diverse Populations: Lessons to apply to Evaluation of Other Instruments, Orlando, FL, November 18, 2005.

Tilley BC. Statistical Issues Related to Clinical Trial Design and Endpoints. Rockville, MD, September 11-13, 2005.

Huang P, **Tilley BC**, Palesch YY, Elm J. Sample size computation for multivariate outcomes. Abstract. The Joint meeting of CSPS/IMS, Beijing, China. March 13, 2005.

Tilley BC, Goetz CG, LaPelle N, Leurgan S, Nyenhuis DL, Stebbins GT, Teresi JA. Clinimetric testing and validation program for the new MDS-sponsored version of UPDRS. The Movement Disorders Society's 9th International Congress of Parkinson's Disease and Movement Disorders, New Orleans, LA, March 5-8, 2005.

Guimaraes P, Kieburtz, Elm, Palesch Y, Huang P, **Tilley, BC**, et al. Non-linearity of Parkinson's clinical progression: Implications for sample size calculations in clinical trials. The Movement Disorders Society's 9th International Congress of Parkinson's Disease and Movement Disorders, Vol. 10, p. S80, New Orleans, LA, March 2005.

Dodel RC, Dubois B, Fahn S, Goetz CG, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees AJ, Leurgans S, LeWitt PA, Martinez-Martin P, Nyenhuis D, Olanow CW, Poewe W, Rascol O, Sampaio C, Schrag A, Stebbins GT, Stern MB, Teresi J, **Tilley BC**, Van Hilten B, et al. Addressing non-motor impairments in Parkinson's disease: The new version of UPDRS. The Movement Disorders Society's 9th International Congress of Parkinson's Disease and Movement Disorders, Vol. 20, p. S83, New Orleans, LA, March 2005.

Elm J, Kamp C, Kieburtz K, Ravina B, Shannon K, Tanner C, Wooten F, Palesch Y, Guimaraes P, Huang P, **Tilley BC**. Treatment Compliance in Parkinson's Disease Clinical Trials: A Comparison of Self-Reported Compliance versus Pill Count. 57th Annual Meeting of the American Academy of Neurology, March 2005.

Tilley BC. Update on clinical trials on stroke in women. The American Heart Association's Second International Conference on Women, Heart Disease, and Stroke, Orlando, FL, February 16-19, 2005.

Frank JC, Jackson JS, Jackson-McCall P, Lantigua R, Lichtenberg PA, Magione CM, Manson, Perez-Stable E, **Tilley BC**. SM, NIA's Resource Centers on Minority Aging Research: Participant Scholar Perspectives and Outcomes. 58th Scientific Meeting of the Gerontological Society of America (GSA), November 18-22, 2005.

ABSTRACTS OR POSTERS, 2004

The NINDS rt-PA Stroke Study Group. Minor stroke: To treat or not to treat with t-PA? Proceedings of the 8th International Symposium on Thrombolysis and Acute Stroke Therapy, Whistler, British Columbia, Canada, 2004, p. 4.

Peng H, **Tilley BC**, Palesch YY, Elm J, Guimaraes P, Swearingen C. Sample size computation for multivariate outcomes. Submitted to ENAR, 2004.

Mazyck P, **Tilley BC**, Lin Y, Simpson K. Barriers to refill medications for chronic diseases in older African Americans. 57th Annual Meeting of the Gerontological Society of America (GSA), Washington, DC, Nov. 2004.

Sadler, Z, **Tilley BC**. An Approach to Estimating the Distribution and Bias of Comparative Fit Indices Using Binary Data. 132nd Annual Meeting (November 6-10, 2004) in Washington, DC. (accepted for Poster presentation)

Magruder K, **Tilley BC**, Miller S, Brown, C, Suarez-Morales, L, Amaro H, Carter R, Haynes L. Program influences on recruitment and retention of minority participants in addictions treatment research. Addiction Services Research Conference, Philadelphia, PA, October 2004.

Nietert PJ, Silver RM, Bolster MB, Mitchell HC, **Tilley BC**, Shaftman SR (2004). The influence of renal disease and race on in-hospital mortality among patients with systemic sclerosis. Presented at the 2004 annual meeting of the American College of Rheumatology. *Arthritis and Rheumatism*; 50 (Suppl): S421-S422.

Nietert PJ, Shaftman SR, **Tilley BC**, Bolster MB, Silver RM (2004). Patterns of emergency room visits in a multi-ethnic population of patients with systemic sclerosis. Presented at the 2004 annual meeting of the American College of Rheumatology. *Arthritis and Rheumatism*; 50 (Suppl): S84-S85.

J. Elm, **B. Tilley**, Y. Palesch, K. Kieburtz, B. Ravina, C. Goetz, C. Kamp, P. Huang, P. Guimaraes, K. Shannon, F. Wooten, CM Tanner. Statistical Issues in Design of Phase II Futility Studies in Parkinson's Disease (PD). The Movement Disorders Society 8th International Conference, Rome Italy June 13-17, 2004

B. Tilley, Y. Palesch, P. Huang, K. Kieburtz, B. Ravina, C. Goetz, C. Kamp, , J. Elm, P. Guimaraes, K. Shannon, F. Wooten, CM Tanner. Statistical Issues in Analysis of a Large Simple Neuroprotection Trial (LST) in Parkinson's Disease (PD). The Movement Disorders Society 8th International Conference, Rome Italy June 13-17, 2004

C. Kamp, A. Shinaman, JD, K. Kieburtz, B. Ravina, **B. Tilley**, A. Brocht, K. Shannon CM Tanner, F. Wooten, Y. Palesch, J. Elm. Do Clinical Trial Infrastructures Impact Enrollment Rates and Baseline Demographics in

Early Parkinson's Disease (PD) Studies? The Movement Disorders Society 8th International Conference, Rome Italy June 13-17, 2004.

Peng Huang, **B.C. Tilley**, B. Ravina, J. Elm, Y. Palesch, K. Bergmann, P. Guimaraes, K. Kiebertz, & Parkinson Study Group. Global Statistical Test (GST) for Parkinson's Disease Clinical Trials. ASENT 5th Annual Meeting Mar, 2004

Jordan J. Elm, **Barbara C. Tilley**, Yuko Y. Palesch, Paulo Guimaraes, Christopher Goetz, Bernard Ravina, Karl Keibertz. In Search of a Short-term Outcome for Parkinson's Disease Futility Studies. ASENT 6th Annual Meeting Mar 11-13, 2004

Guimaraes P, Elm J, Huang P, Palesch Yuko, Kiebertz K, **Tilley, B.** A non-linear mixed model of parkinson's disease progression. The International Biometrics Society/Eastern North American Region (ENAR) with ISM and Sections of ASA 2004 Spring Meeting, March 28-31, 2004, Pittsburgh, PA.

Onitilo A, Lin Y, Okonofua E, **Tilley BC.** Willingness to donate bone marrow: comparison of african americans and Caucasians. 1st Annual Aging Research Day, Center on Aging, MUSC, March 26, 2004, Charleston, SC.

Palesch YY, **Tilley BC.** From bench to bedside: Phase I and II clinical trials for ischemic stroke. Spring Brain Conference, Sedona, AZ, March 2004.

ABSTRACTS OR POSTERS, 2003

Sadler ZE, **Tilley BC**, McLeod-Bryant S, Rust PF, Kaste LM. Ethnic differences in factor structure of lifetime depressive symptoms for young adults in the United States: An investigation of dimensional and configural invariance. Poster Presentation at the 2003 Annual Meeting of the American Public Health Association, San Francisco, CA.

ABSTRACTS OR POSTERS, 2002

Palesch Y, Tilley, BC. The value of single-arm phase II trials for stroke therapeutics. ISCB 2002 Conference.

The APASS Study Group. Antiphospholipid antibodies and recurrent thrombo-occlusive events: The antiphospholipid antibodies and stroke study (APASS). The 54th Annual Meeting of the American Academy of Neurology, San Antonio, TX, February 2002.

ABSTRACTS OR POSTERS, 2001

Tilley, BC, McLeod-Bryant, Hoskins D, Blue A, Spruill I. Developing cultural competence in providers of healthcare to older African Americans. Gerontological Society of America 54th Annual Scientific Meeting, Chicago, IL, November 2001.

ABSTRACTS OR POSTERS, 2000

The WARSS/APASS Collaborative Group. Baseline, frequencies, isotypes, and titers of antiphospholipid antibodies in the Warfarin Aspirin Recurrent Stroke Study/ Antiphospholipid Antibody Study

(WARSS/APASS) collaboration. 25th American Heart Association International Stroke Conference, New Orleans, February 2000.

Pratt CA, **Tilley BC**, Levine S, Chopp M, Chase G. Stroke knowledge, prevention practices, and preferred approaches to stroke education: Towards developing a new ethnically specific, culturally sensitive survey tool. 25th American Heart Association International Stroke Conference, New Orleans, February.

ABSTRACTS OR POSTERS, 1999

The WARSS/APASS/PICSS/HAS/GENEIS Collaboration Group. Representativeness of nonrandomized substudies within a randomized trial: The WARSS Collaboration. 24th American Heart Association International Conference on Stroke and Cerebral Circulation, Nashville, February.

Marler JR, **Tilley BC**, Lu M, Brott T, Lyden P, Broderick JP, Grotta J, Levine SR, Frankel M, Horowitz S, Kwaitkowski T, The NINDS rt-PA Stroke Study Group. Earlier Treatment Associated with Better Outcome in the NINDS TPA Stroke Study. 24th American Heart Association International Conference on Stroke and Cerebral Circulation, Nashville, February.

Tilley BC. Lack of Use of Imputation in Clinical Trials, S. C. Chapter of the American Statistical Association, Charleston, SC, April.

Tilley BC. Lack of Use of Imputation in Clinical Trials, The International Biometric Society, Eastern North American Region (ENAR) 1999 Spring Meeting, Atlanta, GA, March.

Tilley B. Developing Across Center Collaborations: Experience of the Resources Centers on Minority Research. Gerontological Society of America 52nd Annual Scientific Meeting, October 1999, Vol. 39, Special Issue 1, p. 29, San Francisco.

Tilley BC. Issues in Measuring Health Related Concepts in Minority Aging Research. Gerontological Society of America, 52nd Annual Scientific Meeting, San Francisco, November, Vol. 39, Special Issue 1, p. 388, October 1999.

Pratt C, **Tilley B**, Chopp M, Chase G. Stroke knowledge, stroke risk and stroke prevention practices of elderly African Americans. Gerontological Society of America 52nd Annual Scientific Meeting, October 1999, Vol. 39, Special Issue 1, p. 533, San Francisco.

ABSTRACTS OR POSTERS, 1998

Myers R, **Tilley BC**, Vernon SW, Kristal A, Glanz K. The Next Step Trial: Impact of a Worksite Colorectal Cancer Screening Promotion Program, APHA Annual Meeting in Washington, D.C., November.

Glanz K, **Tilley BC**, Myers R, Vernon SW, Kristal A. Nutrition Intervention for High-Risk Auto Workers: Results of the Next Step Trial. AHPA Annual Meeting in Washington, D.C., November.

Tilley BC, N Geller. A Critical Assessment of Meta-analysis for Thrombolysis. 5th International Symposium on Thrombolytic Therapy in Acute Ischemic Stroke, Bethesda, Maryland, May.

The NINDS t-PA Stroke Trial Study Group. Effect of rt-PA on Ischemic Stroke Lesion Size by Computed Tomography: Preliminary Results from the NINDS t-PA Stroke Trial. 23rd International Joint Conference on Stroke and Cerebral Circulation, American Heart Association, Orlando, February.

Kwaitkowski TG, Libman R, Frankel M, **Tilley B**, Morganstern L, Lu M, Broderick J, Marler J, Brott T and the NINDS rt-PA Stroke Trial Study Group. The NINDS rt-PA Stroke Study: Sustained Benefit at One Year. 23rd International Joint Conference on Stroke and Cerebral Circulation, American Heart Association, Orlando, February.

ABSTRACTS OR POSTERS, 1997

NINDS rt-PA Stroke Trial Study Group. Generalized Efficacy of t-PA for Acute Stroke: Subgroup Analysis of the NINDS t-PA Stroke Trial. 22nd International Joint Conference on Stroke and Cerebral Circulation, American Heart Association, Anaheim, February.

NINDS rt-PA Stroke Trial Study Group. Symptomatic Intracerebral Hemorrhage After t-PA for Stroke. 22nd International Joint Conference on Stroke and Cerebral Circulation, American Heart Association, Anaheim, February.

Fagan S, Morgenstern L, Petitta A, Ward RE, **Tilley BC**, Marler J, Broderick J, Levine S, Kwaitkowski T, Frankel M, Walker MD, and the NINDS rt-PA Stroke Study Group. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. 22nd International Joint Conference on Stroke and Cerebral Circulation, American Heart Association, Anaheim, February.

Ford ME, Edwards G, Rodriguez J, Gibson RC, **Tilley BC**. An asthma education program for African American adults. First Annual African American Health Summit, Detroit, August.

Ford ME, Havstad SL, **Tilley BC**. Perceptions of diabetes: a life span perspective. Annual Conference of the Gerontological Society of America, Cincinnati, November.

Havstad SL, Borzak S, Joseph CLM, Gheorghide M, **Tilley BC**. Lower Thrombolytic Use for African Americans with Myocardial Infarction: An Influence of Clinical Presentation: Poster presentation, Association for Health Services Research 14th Annual Meeting, Chicago, June.

Alarcón GS, **Tilley BC**, Shuhui L, Pillemer S, Mikhail IS, for the MIRA Trial Group. Self-Administered (SA) joint counts (SA-JCs) are not a substitute for standard Jcs in RA clinical trials (CITr), American College of Rheumatology.

Tilley BC. Analysis of multiple outcomes in the NINDS t-PA Stroke Trial. DIA Annual Meeting, Montreal, June.

Blixen C, Havastad S, **Tilley BC**, Zorratti E, a comparison of healthcare resource use between African Americans and Caucasians hospitalized with asthma. The Association for Health Services research (AHSR), 14th Annual meeting, Chicago, June.

Blixen C, Havastad S, **Tilley BC**, Zorratti E., A comparison of healthcare resource use between African Americans and Caucasians hospitalized with asthma. The American Lung Association/American Thoracic Society International Conference, San Francisco, May.

Tilley BC. Global tests for clinical trials with multiple outcomes. Midwest Biopharmaceutical Statistics Workshop, Muncie, May.

ABSTRACTS OR POSTERS, 1996

Tilley BC. NINDS t-PA Stroke Trial: Methods Including Global Endpoint. 21st International Joint Conference on Stroke and Cerebral Circulation, American Heart Association, San Antonio, February.

Blixen C, **Tilley BC**, Havstad S, Zoratti E. Quality of life, medication use, and health care utilization of urban African-Americans seen in emergency departments with asthma. Annual American College of Allergy, Asthma & Immunology Meeting, Boston, November.

Thompson JLP, Brey RL, **Tilley BC**, Sacco RL, Levin B, Mohr JP, Levine SR. The WAARS/APASS collaboration: Management and statistical issues in a multi-study clinical trial involving antiphospholipid antibodies. 7th International Symposium on Antiphospholipid Antibodies, New Orleans, October.

McDonald P, **Tilley BC**, Havstad S. Nurses perceptions: Issues that arise in caring for patients with diabetes in a managed care environment. Association for Health Services Research, Atlanta, June.

Tilley BC. Improving quality of care for African Americans: the experience of the Center for Medical Treatment Effectiveness Programs in a managed care environment. Association for Health Services Research, Atlanta, June.

Ford ME, Havstad SL, Lamerato L, **Tilley BC.** Racial differences in diabetes perceptions. Association for Health Services Research, Atlanta, June.

Tilley BC, Lu M, for NINDS t-PA Trial Investigators. Analytical Issues for Stroke Clinical Trials. Society for Clinical Trials, Pittsburgh, May.

Hirst K, **Tilley BC**, Lu M. Extending Intent-to-treat Principles to Cluster Design Clinical Trials. Society for Clinical Trials, Pittsburgh, May.

Tilley BC, Holmgren E, Lu M, Wan-Clow F. Relative Risk Estimates for Global Tests. The Eastern Region International Biometric Society Meetings, Richmond, March.

Vernon S, Myers R, Lu M, **Tilley BC.** Factors Associated with Perceived Susceptibility to Colorectal Cancer. American Society of Preventive Oncology, March.

Myers R, Vernon S, Lu M, **Tilley BC.** Factors Related to Employee Intention to Engage in Worksite Colorectal Screening. American Society of Preventive Oncology, March.

Joseph CLM, Ownby DR, **Tilley BC.** Ethnic Differences in Biologic Factors Related to Childhood Asthma. American Academy of Allergy Asthma and Immunology, March.

ABSTRACTS OR POSTERS, 1995

Graddy-Dansby G, Robinson VL, Thompson-Cardwell K, Havstad S, Shepard A, **Tilley BC**, Young M. Risk factors comorbidities and gangrene do not explain racial differences in amputation rates of African American diabetics. Society for Medical Decision Making, October.

Joseph CLM, Havstad SL, Johnson CC, **Tilley BC.** Validation of the effects of visits to allergist on the ethnic differential in emergency department use for asthma. American Academy of Allergy and Immunology, July.

Wisdom K, Ford M, **Tilley BC.** A diabetes empowerment educational program for African American adults. American Diabetes Association, June.

Ford M, Havstad SL, **Tilley BC**, Bolton MB. Ethnic differences in the effects of asthma education on health beliefs and health behavior. Association of Health Services Research, June.

Joseph CLM, Havstad SL, Johnson CC, **Tilley BC**. Asthma management in African American children. Society for Epidemiologic Research, June.

Wisdom K, Fryzek JP, Dreiling MC, Havstad SL, **Tilley BC**. Race-specific differences in diabetes care determined using computerized data. American Diabetes Association, May.

Havstad SL, Joseph CLM, Ford M, Bolton MB, **Tilley BC**. Effectiveness of an asthma education intervention in African Americans. Society of General Internal Medicine, April.

Tilley BC, Heyse SP, Rusinova M, Glegg DO, Global tests for clinical trials with multiple outcomes. The Society for Clinical Trials Meeting 16th Annual Meeting, April-May, Seattle WA.

ABSTRACTS OR POSTERS, 1994

Tuttleman M, Pillemer S, **Tilley BC**, Fowler S, Buckley L, Alarcón G, Trentham D, Neuner R, Clegg D, Leisen J. Assessment of health status instruments in a rheumatoid arthritis (RA) clinical trial. Annual Scientific Meeting of the American College of Rheumatology, 29th Annual Meeting.

Tilley BC, Heyse SP, Rusinova M, Clegg DO. Global outcome test for rheumatoid arthritis trials. Annual Scientific Meeting of the American College of Rheumatology, 29th Annual Meeting.

Bluhm GB, Sharp JT, **Tilley BC**, Rusinova M, Alarcón GS, Heyse SP, Trentham DE, Neuner R, Kaplan DA, Clegg DO, Leisen JCC, Buckley L, Cooper SM, Duncan H, Pillemer, SR, Tuttleman M, Fowler SE. Radiographic results from the minocycline in rheumatoid arthritis trial (MIRA). Annual Scientific Meeting of the American College of Rheumatology; 29th Annual Meeting.

Reveille JD, Alarcón GS, Fowler SE, Pillemer S, Neuner, R, Clegg DO, Trentham D, Leisen J, Cooper S, Duncan H, Mikhail I, Tuttleman M, Heyse S, **Tilley BC**. Lack of a gene-dose effect for the "rheumatoid" epitope in RA patients from a large multicenter clinical trial. Annual Scientific Meeting of the American College of Rheumatology; 29th Annual Meeting.

Tilley BC. Design of the NINDS t-PA Stroke Trial (poster). 19th International Joint Conference on Stroke and Cerebral Circulation, American Heart Association, San Diego, February.

Tilley BC, Heyse S, Clegg D. Global outcome tests for rheumatoid arthritis trials. Society for Clinical Trials. Society for Clinical Trials, 15th Annual Meeting, 1994.

Vernon SW, **Tilley BC**, Glanz K, Myers R, Sanders KL, Lu M. Planning the Next Step: A screening promotion and nutrition intervention trial in the worksite. Society for Clinical Trials; 15th Annual Meeting.

Tilley BC, Marler J, Geller N, Legler J, Ryan R. Using a global outcome test in stroke trials. International Biometric Conference.

ABSTRACTS OR POSTERS, 1993

Gheorghide M, Young M, Uretsky F, Packer G, Havstad S, **Tilley BC**. Predicting clinical deterioration after digoxin withdrawal in heart failure: Insights from the PROVED and RADIANCE trials. XVth Congress of the European Society of Cardiology.

Rybicki B, **Tilley BC**, Johnson CC. How beneficial is multiple endoscopy screening in detecting adenomatous polyps? Society for Epidemiologic Research.

Tilley BC. Approaches to reducing the cost of clinical trials. Statistical Issues in the Pharmaceutical Industry: Design, Analysis and Interpretation Issues in Clinical Trials. Drug Information Association, Hilton Head.

Tilley BC, for the MIRA Trial Investigators Participating Clinics. Recruitment strategies in rheumatoid arthritis (RA) clinical trials (CT):the MIRA experience. Society for Clinical Trials, 14th Annual Meeting.

ABSTRACTS OR POSTERS, 1992

NINDS Trial Investigators (**Tilley, presenter**). A Deming approach to recruiting: The National Institutes of Neurological Disorders and Stroke (NINDS) t-PA Stroke Trial Experience. Poster Session, Society for Clinical Trials, May 1992.

Johnson CC, Uman J, **Tilley BC**, Sandler M. Prevalence of abdominal aortic aneurysms. Society for Epidemiologic Research.

Niland, Odon-Maryon, **Tilley BC**. A survey of biostatistical units throughout North America. Joint Statistical Meetings.

Rybicki B, Johnson CC, Visintainer P, **Tilley BC**. Incidence of adenomatous polyps of the sigmoid colon in an occupational cohort. Society for Epidemiologic Research.

Tilley BC. A Deming approach to recruiting: The National Institutes of Neurological Disorders and Stroke (NINDS) - t-PA stroke trial experience. 2nd International Symposium on Thrombolytic Therapy in Acute Ischemic Stroke.

Tilley BC. Good science in a bad economy: Issues in cardiovascular and cerebrovascular clinical trials. Joint Statistical Meetings.

Uman J, Sandler M, Johnson CC, **Tilley BC**. Prevalence of abdominal aortic aneurysms. American Heart Association.

Tilley BC. Systems Analysis: How this can improve the care of your emergency CVA patients. Michigan College of Emergency Physicians.

ABSTRACTS OR POSTERS, 1991

Tilley BC, Schultz LR. Subgroup analyses in clinical trials: An exploration. American Public Health Association.

ABSTRACTS OR POSTERS, 1990

Tilley BC, Brown E, Gretchen T, Deveshwar R, Ramadin N, Levine S, Dietrich K, and Welch KMA. Outcome measurements in clinical trials for stroke patients. Society for Clinical Trials.

Johnson CC, Feingold ML, **Tilley BC**. Meta-analysis of herbicide exposure and risk for soft tissue sarcoma and lymphoma. American Public Health Association.

Tilley BC. When a coordinating center assumes an ongoing trial. Society for Clinical Trials, Eleventh Annual Meeting, Toronto, May.

ABSTRACTS, 1989

Tilley BC, Johnson CC, Joseph CLM, et al. Colon cancer mortality among automotive industry pattern and model makers. Society for Epidemiology Research.

Joseph CLM, Johnson CC, Strauchman C, **Tilley BC.** Cost of case ascertainment in a cohort of non-respondents. American Public Health Association.

Tilley BC, Peterson EP, Kleerekoper M, Riggs W, O'Fallon Wm. Endpoint in osteoporosis clinical trials. International Society for Clinical Biostatistics, Maastricht.

Tilley BC, Nelson DA, Peterson EL, O'Fallon Wm, Riggs BC, Kleerekoper M. Vertebral fracture as an endpoint for trials in osteoporosis: the reliability of digitizing techniques for vertebral area measurements. Society for Clinical Trials, May.

ABSTRACTS, 1988

Schultz LR, Johnson CC, **Tilley BC,** Model Selection of Substance Abusers from a Large Work Force. Eastern North American Region Biometric Society Meeting, Boston, March.

ABSTRACTS, 1987

Neale AV, **Tilley BC,** Vernon SW. Marital status, delay in seeking treatment, and survival from breast cancer. Behavioral Medicine Abstracts, 1987;8:92(#82-0366).

WORKSHOPS/INVITED TALKS

Tilley BC (instructor) Clinical Trial Statistics. American Society for Experimental Neurotherapeutics 9th Annual Meeting, Washington, DC, March, 2007.

Tilley BC (speaker) Scholars Lecture, Scholars Seminar Series. Recruiting Diverse Populations into Studies of Rare Diseases: A Mixed Methods Approach. University of Arizona, Tucson, Arizona, February, 2007.

Tilley BC (speaker) University of South Florida Seminar Series. Using Mixed Methods to Develop a Recruitment Approach for Diverse Populations with Parkinson's Disease. University of South Florida, Tampa, FL, January, 2007.

Tilley, BC (participant) National Institute of Neurological Disorders and Stroke Progress Review Group Member, Charleston, SC, September, 2006.

Tilley BC (speaker) Designing stroke trials. American Society for Experimental NeuroTherapeutics (ASENT) 4th Annual Meeting. Workshop #1 - Statistical Concepts in the Design and Interpretation of Clinical Trials in Neuroscience, Washington, DC, March 2002.

Tilley BC (speaker) Overview of Resources Centers on Minority Aging Research (RCMAR). EXCEED Pre-conference workshop on Measurement Issues in Health Disparities Research in the U.S. Conference, San Francisco, May 2001.

Tilley BC (Chair) Resource Centers for Minority Aging Research Third Annual Meeting, Bethesda, MD, sponsored by NIA/NIH, Bethesda, MD, April 2001.

Tilley BC (speaker) Issues in the Design and Analysis of Ischemic Stroke Trials: Phase II-Phase III. DIA Workshop: Innovative Statistical Strategies: A Competitive Advantage in the Global Drug Development Process, Savannah, GA, March 2001.

Tilley BC (speaker) Research in Minority Aging: Achieving Health Equity. Millennium Series Symposium, Nutrition and Aging: Leading a Healthy, Active Life, Washington, DC, sponsored by the USDA, Center for Nutrition Policy and Promotion, September 2000.

Tilley BC (participant) Stroke Drug Development: Improving Clinical Trial Design and Endpoint Selection. Stroke Treatment Academia, Industry; Roundtable II (STAIR), March 9-10, 2000, Redwood City, CA.

Tilley BC (Chair) Resource Centers for Minority Aging Research Second Annual Meeting, Bethesda, MD, sponsored by NIA/NIH, Bethesda, MD, February 2000.

Tilley BC (speaker) Neuroprotection in Acute Cerebral Ischemia Conference. Pinehurst, NC, February 2000.

Tilley BC (Review Participant) National Cancer Institute's Colorectal Cancer Progress Review Group Roundtable Meeting, San Francisco, CA, January 2000.

Tilley BC (Chair) Resource Centers for Minority Aging Research Second Annual Meeting, Bethesda, sponsored by NIA/NIH, Bethesda, MD, February 1999.

Tilley BC (invited speaker) Epidemiological and Biostatistical Issues in the Design of Laboratory Studies, 1999 Carolinas Clinical Connection, Charleston, SC March, 1999.

Tilley BC (Co-Chair) Improving Blood Pressure Control: Experts in Hypertension Education Series, sponsored by Medical University of South Carolina, Charleston, SC, April 1999.

Tilley BC (Panel member) Issues Regarding the Principles and Practice of Clinical Trials in Neurological Disorders, Boston, June 1999.

Tilley BC (speaker) Gerontological Society of America Workshop: Involving Older Ethnic Minorities in Health Related Research. San Francisco, CA, November 1999.

Tilley BC (speaker) An Outsider's Perspective on Current and Possible Antiepileptic Drug Clinical Trial Designs, sponsored by American Epilepsy Society, San Diego, California, December 1998.

Tilley BC (invited participant) Developing a Minority Health Services Research Agenda, sponsored by Association of American Medical Colleges and the Agency for Health Care Policy and Research, Chantilly, Virginia, July 1997.

Tilley BC (organizer and speaker) Workshop on global tests for clinical trials with multiple outcomes. Society for Clinical Trials, May 1995.

Tilley BC. (Panel member) Consensus development conference on optimal calcium intake. National Institute of Arthritis and Musculoskeletal and Skin Diseases. June 1994.

Tilley BC. (Chair) Analysis of multiple endpoints in a clinical trial. National Institute of Neurologic Disorders and Stroke. November 1993.

Tilley BC. Statistical issues in the design of animal studies. Humane Care and Use of Laboratory Animals. Wayne State University. May 1992.

Tilley BC. Designing animal studies: Sample size and other statistical issues. Michigan Society for Medical Research (MISMR), Ann Arbor, Michigan. September 1990.

PUBLICATIONS RELATED TO DATA AND SAFETY MONITORING ACTIVITIES FOR NIH

Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A Clinical Trial of Estrogen-Replacement Therapy after Ischemic Stroke, *NEJM* 2001;1345:1243-9.

Klempner MS, Hu LT, Evans J, Schmid CH, Johnson GM, Trevino RP, Norton D, Levy L, Wall D, McCall J, Kosinski M, Weinstein A. Two Controlled Trials of Antibiotic Treatment in Patients with Persistent Symptoms and a History of Lyme Disease, *NEJM* 2001;345:85-92.

Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N, and other NSABP Investigators. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.[see comment]. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] *Journal of the National Cancer Institute.* 1998;90:1371-88.

TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non q-wave myocardial infarction: Results of the TIMI IIIB Trial. *Circulation* 1994;84:1545-56.

Mandel JS, Bond JH, Church TR, Snover DC, Bradley M, Schuman LM, Ederer F, for the Minnesota Colon Cancer Control Study. Reducing mortality from colorectal cancer by screening for fecal occult blood. *NEJM* 1993;328:1365-1371.

MUSC COMMITTEES

Current:

Member, Southeastern Clinical and Translational Research Center (SECTR)

Member, Cancer Prevention and Control Recruitment Committee

Member, Mentoring Committee, COM

Member, Advisory Committee to BIRCH grant

Member, Society of Women Scholars

Member, Charleston VA TREP Steering Committee

Member, Advisory Committee for Rehabilitative Medicine, COM

Member, Advisory committee for the Program for Movement, Exercise, and Rehabilitation Research (PMERR)

Member, General Clinical Research Center Advisory Committee

Previous:

Member, Southern Consortium Advisory Board for the Clinical Trials Network (CTN), Institute of Psychiatry

Member, Chair Search, Surgery, COM

Member, Chair Search, Anesthesiology and Perioperative Medicine. COM

Member, Clinical Trials Data Safety and Monitoring Board, Hollings Cancer Center
Appointments, Promotions and Tenure Committee
Coastal Cancer Control Planning Committee
Gender Issues Committees
Hypertension Center Planning Committee
Mission Based Management Steering Committee
Mission Based Management, Education Team Subcommittee
Center for Health Care Research (CHCR) Advisory Committee
Chair, Dean of Graduate Studies Search Committee
Chair, Hollings Cancer Center, Associate Director, Prevention and Population Science Search Committee
Member, Vice President for Medical Affairs & College of Medicine Dean Search Committee
Chair, Center for Health Care Research Director Search Committee
Member, College of Medicine, LCME Self-Study Task Force, Graduate Education in the Basic Sciences Subcommittee
Member, HCC P-30 Planning Committee
Member, MSCR K30 Planning Committee
Member, Elsie Taber Society of Scholars
Member, Clinical Research Task Force, COM

TEACHING ACTIVITIES

Students:

Primary Advisory

Zara Sadler (Ph.D. program) 2001-2004
Christopher Khedouri (Ph.D. program) 2001-2004
Chengwu Yang (PhD. Program)
Christopher Swearingin 2006 -

Advisory

Theodosha S Gilliard (M.S. program) 2003
Jordan Elm (Ph.D. program) 2003 -
Ryan Dickson (M.S. program) 2003
Winnie Hennessey (Ph.D. program) 2002
Rickey Carter (Ph.D. program) 2000 -2002
Ewing JR. A nuclear magnetic resonance measurement of cerebral perfusion: the use of gaseous halocarbons in an indicator dilution technique. Oakland University, graduated 1992 (Currently at Henry Ford Health System; on faculty at CWRU)

MSCR Advisory

Denise Fyffe 2004-2006
Jennifer Mazyck-Brown -2005
Pamela Mazyck (graduated, Aug 05) 2003 – 2005
Johannah Uriri Glover 2003-2005
Sharie Haugabook 2003-2005
Matthew Quintero 2003-2005

Postdoctoral Fellow

Paulo Guimaraes, Ph.D., 2002-2004 (Currently on faculty at University of South Carolina)
Patricia MacDonald, Ph.D., post doctoral nursing student from Case Western Reserve University, 1995-1996. (Currently on faculty at CWRU)

Supervisor of graduate student and medical student summer interns (Henry Ford Health System, 1987 –1999.

Mentoring:

Through AHRQ-funded MEDTEP Project, NIA-funded Resource Center on Minority Aging, and AHRQ-funded EXCEED mentored and continue to mentor numerous new minority investigators.

Courses Taught

- Independent Study on Beyond Anova, University of Michigan, 1990.
- Design and Analysis of Clinical Trials, University of Michigan, 1985-1986.
- Biostatistics and Epidemiology Core Course, Henry Ford Health Sciences Center, 1990, 1991, 1994 (Clinical Trials).
- Regression Analysis for Health Services, University of Michigan, 1984-1985.
- Statistical Collaboration, 2000, 2001
- Grant Development, 2001, 2002, 2003, 2004, 2005, 2006, 2007
- Statistical Methods for T32, 2006, 2007

Last updated 1/09/09